A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting

References

• Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgrad Med. 2011;123(5):194–204.
   PubMed Web of Science ®Google Scholar
• Gad S. Post-marketing safety evaluation: monitoring, assessing, and reporting of adverse drug responses. Second Edition. Evaluation DS, editor. Hoboken New Jersey: John Wiley & Sons; 2009.
   Google Scholar
• Sn Dc P, Falzon D, et al. WHO strategy for collecting safety data in public health programs: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75–81.
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14(1):10.
   PubMed Web of Science ®Google Scholar
• Reed CE, Fenton SE. Exposure to diethylstilbestrol during sensitive life stages: a legacy of heritable health effects. Birth Defects Res C Embryo Today. 2013;99(2):134–146.
   PubMedGoogle Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21): 1520–8, 2 p following 8.
   Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136–147.
   PubMed Web of Science ®Google Scholar
• Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. Jama. 1997;277(4):301–306.
   PubMed Web of Science ®Google Scholar
• Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997;25(8):1289–1297.
   PubMed Web of Science ®Google Scholar
• Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments. Drug Saf. 2012;35(9):769–781.
   PubMed Web of Science ®Google Scholar
• Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73–7.
   PubMedGoogle Scholar
• Kalisch LM, Caughey GE, Roughead EE, et al. The prescribing cascade. Aust Prescr. 2011;34(6):162–166.
   Web of Science ®Google Scholar
• Wilson RM, Runciman WB, Gibberd RW, et al. The quality in Australian health care study. Med J Aust. 1995;163(9):458–471.
   PubMed Web of Science ®Google Scholar
• Li R, Curtis K, Zaidi STR, et al. Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions. Expert Opin Drug Saf. 2021;20(10):1267–1274.
   Web of Science ®Google Scholar
• Porterfield A, Engelbert K, Coustasse A. Electronic prescribing: improving the efficiency and accuracy of prescribing in the ambulatory care setting. Perspect Health Inf Manag. 2014;11(Spring):1g.
   PubMedGoogle Scholar
• Yoon D, Park MY, Choi NK, et al. Detection of adverse drug reaction signals using an electronic health records database: comparison of the laboratory extreme abnormality ratio (CLEAR) algorithm. Clin Pharmacol Ther. 2012;91(3):467–474.
   PubMed Web of Science ®Google Scholar
• Leslie H. Electronic medication management. Stud Health Technol Inform. 2010;151:269–277.
   PubMedGoogle Scholar
• Ventola CL. Mobile devices and apps for health care professionals: uses and benefits. P T. 2014;39(5):356–364.
   PubMedGoogle Scholar
• Wong A, Plasek JM, Montecalvo SP, et al. Natural language processing and its implications for the future of medication safety: a narrative review of recent advances and challenges. Pharmacotherapy. 2018;38(8):822–841.
   PubMed Web of Science ®Google Scholar
• Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018;2(10):719–731.
   PubMed Web of Science ®Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396.
   PubMed Web of Science ®Google Scholar
• Al Dweik R, Stacey D, Kohen D, et al. Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol. 2017;83(4):875–883.
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.
   PubMed Web of Science ®Google Scholar
• Li R, Zaidi STR, Chen T, et al. Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: a systematic review. Pharmacoepidemiol Drug Saf. 2020;29(1): 1–8.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, et al. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf. 2013;36(5):317–328.
   PubMed Web of Science ®Google Scholar
• Paudyal V, Al-Hamid A, Bowen M, et al. Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(9):1173–1191.
   PubMed Web of Science ®Google Scholar
• Kasliwal R. Spontaneous reporting in pharmacovigilance: strengths, weaknesses and recent methods of Analysis. The J Clin Preven Cardio. 2012;1:20–23.
   Google Scholar
• Li R, Curtis K, Zaidi STR, et al. Effect of the black triangle scheme and its online educational campaign on the quantity and quality of adverse drug event reporting in Australia: a time series analysis. Expert Opin Drug Saf. 2020;19(6):747–753.
   PubMed Web of Science ®Google Scholar
• Ribeiro A, Lima S, Zampieri ME, et al. Filling quality of the reports of adverse drug reactions received at the pharmacovigilance centre of Sao Paulo (Brazil): missing information hinders the analysis of suspected associations. Expert Opin Drug Saf. 2017;16(12):1329–1334.
   PubMed Web of Science ®Google Scholar
• Balidemaj F, editor Adverse drug reactions: problems with spontaneous reporting systems and communicating information to providers to improve reporting rate globally 2013.
   Google Scholar
• Lewis MA, Kühl-Habich D, von Rosen J. Drug use and adverse event monitoring in German children. Int J Clin Pharmacol Ther. 2001;39(11):507–512.
   PubMed Web of Science ®Google Scholar
• Lacoste-Roussillon C, Pouyanne P, Haramburu F, et al. Incidence of serious adverse drug reactions in general practice: a prospective study. Clin Pharmacol Ther. 2001;69(6):458–462.
   PubMed Web of Science ®Google Scholar
• Heeley E, Riley J, Layton D, et al. Prescription-event monitoring and reporting of adverse drug reactions. Lancet. 2001;358(9296):1872–1873.
   PubMed Web of Science ®Google Scholar
• González-Rubio F, Calderón-Larrañaga A, Poblador-Plou B, et al. Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study. Pharmacoepidemiol Drug Saf. 2011;20(12):1287–1294.
   PubMed Web of Science ®Google Scholar
• Grange JC. A general practitioner’s one year record of adverse drug reactions. Therapie. 2012;67(3):237–242.
   PubMed Web of Science ®Google Scholar
• Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ (Clinical research ed). 2000;320(7241):1036.
   PubMed Web of Science ®Google Scholar
• Bäckström M, Mjörndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2004;13(7):483–487.
   PubMed Web of Science ®Google Scholar
• Rydberg DM, Holm L, Engqvist I, et al. Adverse drug reactions in a tertiary care emergency medicine ward - prevalence, preventability and reporting. PLoS One. 2016;11(9):e0162948.
   PubMed Web of Science ®Google Scholar
• Dittrich ATM, Draaisma JMT, van Puijenbroek EP, et al. Analysis of reporting adverse drug reactions in paediatric patients in a university hospital in the Netherlands. Pediatr Drugs. 2020;22(4):425–432.
   PubMed Web of Science ®Google Scholar
• Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions. Drug Saf. 2004;27(7):477–487.
   PubMed Web of Science ®Google Scholar
• Khalili M, Mesgarpour B, Sharifi H, et al. Estimation of adverse drug reaction reporting in Iran: correction for underreporting. Pharmacoepidemiol Drug Saf. 2021;30(8):1101–1114.
   PubMed Web of Science ®Google Scholar
• Li R, Curtain C, Bereznicki L, et al. Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Int J Clin Pharm. 2018;40(4):878–889.
   PubMed Web of Science ®Google Scholar
• Herdeiro MT, Figueiras A, Polonia J, et al. Physicians’ attitudes and adverse drug reaction reporting: a case-control study in Portugal. Drug Saf. 2005;28(9):825–833.
   PubMed Web of Science ®Google Scholar
• Gahr M, Connemann B, Zeiss R, et al. Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey. Expert Opin Drug Saf. 2021;20(8):979–985.
   Web of Science ®Google Scholar
• Haines HM, Meyer JC, Summers RS, et al. Knowledge, attitudes and practices of health care professionals towards adverse drug reaction reporting in public sector primary health care facilities in a South African district. Eur J Clin Pharmacol. 2020;76(7):991–1001.
   PubMed Web of Science ®Google Scholar
• Kc S, Tragulpiankit P, Gorsanan S, et al. Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal. BMC Pharmacol Toxicol. 2013;14(1):16.
   PubMedGoogle Scholar
• Hadi MA, Helwani R, Long CM. Facilitators and barriers towards adverse drug reaction reporting: perspective of Malaysian hospital pharmacists. J Pharm Health Serv Res. 2013;4(3):155–158.
   Google Scholar
• Mirbaha F, Shalviri G, Yazdizadeh B, et al. Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach. Implement Sci. 2015;10(1):110.
   PubMed Web of Science ®Google Scholar
• Terblanche A, Meyer JC, Godman B, et al. Knowledge, attitudes and perspective on adverse drug reaction reporting in a public sector hospital in South Africa: baseline analysis. Hosp Pract. 2017;45(5):238–245.
   PubMedGoogle Scholar
• Moinuddin K, Ali S, Al-Aqqad AQ, et al. Knowledge and attitude of health-care professionals toward adverse drug reactions reporting at king saud medical city. J Pharm Bioallied Sci. 2018;10(1):29–34.
   PubMed Web of Science ®Google Scholar
• Nisa ZU, Zafar A, Sher F. Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the capital of Pakistan. Saudi Pharm J. 2018;26(4):453–461.
   PubMed Web of Science ®Google Scholar
• AlShammari TM, Almoslem MJ. Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: a multi-centre cross sectional study. Saudi Pharm J. 2018;26(7):925–931.
   PubMed Web of Science ®Google Scholar
• Kassa Alemu B, Biru TT. Health care professionals’ knowledge, attitude, and practice towards adverse drug reaction reporting and associated factors at selected public hospitals in northeast Ethiopia: a cross-sectional study. Biomed Res Int. 2019;2019:8690546.
   PubMed Web of Science ®Google Scholar
• Hughes ML, Weiss M. Adverse drug reaction reporting by community pharmacists—The barriers and facilitators. Pharmacoepidemiol Drug Saf. 2019;28(12):1552–1559.
   PubMed Web of Science ®Google Scholar
• Le TT, Nguyen TTH, Nguyen C, et al. Factors associated with spontaneous adverse drug reaction reporting among healthcare professionals in Vietnam. J Clin Pharm Ther. 2020;45(1):122–127.
   PubMed Web of Science ®Google Scholar
• Güner MD, Ekmekci PE. Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. J Drug Assess. 2019;8(1):13–20.
   PubMed Web of Science ®Google Scholar
• Adegbuyi TA, Fadare JO, Araromi EJ, et al. Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals working in primary, secondary and tertiary healthcare facilities in Ekiti State, South-West Nigeria. Hosp Pharm. 2021;56(6):751–759.
   Web of Science ®Google Scholar
• Li R, Curtis K, Van C, et al. Why hospital based healthcare professionals do not report adverse drug reactions: a mixed methods study using the theoretical domains framework. Eur J Clin Pharmacol. 2022;78(7):1165–1175.
   Web of Science ®Google Scholar
• Tanti A, Camilleri M, Borg AA, et al. Opinions of maltese doctors and pharmacists on medication errors. Int J Risk Saf Med. 2017;29(1–2):81–99.
   PubMed Web of Science ®Google Scholar
• Atkins L, Francis J, Islam R, et al. A guide to using the theoretical domains framework of behaviour change to investigate implementation problems. Implement Sci. 2017;12(1):77.
   PubMed Web of Science ®Google Scholar
• Bukirwa H, Nayiga S, Lubanga R, et al. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health. 2008;13(9):1143–1152.
   PubMed Web of Science ®Google Scholar
• Braun LA, Tiralongo E, Wilkinson JM, et al. Adverse reactions to complementary medicines: the Australian pharmacy experience. Int J Pharm Pract. 2010;18(4):242–244.
   PubMedGoogle Scholar
• van Hunsel F, van der Welle C, Passier A, et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66(11):1143–1150.
   PubMed Web of Science ®Google Scholar
• Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234, iii–iv.
   Web of Science ®Google Scholar
• Krska J, Jones L, McKinney J, et al. Medicine safety: experiences and perceptions of the general public in Liverpool. Pharmacoepidemiol Drug Saf. 2011;20(10):1098–1103.
   PubMed Web of Science ®Google Scholar
• Lorimer S, Cox A, Langford NJ. A patient’s perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37(2):148–152.
   PubMed Web of Science ®Google Scholar
• Salvo F, Miroddi M, Alibrandi A, et al. Attitudes and opinion about adverse drug events of women living in a city of south Italy. Pharmacology. 2013;91(3–4):173–177.
   PubMed Web of Science ®Google Scholar
• Arnott J, Hesselgreaves H, Nunn AJ, et al. What can we learn from parents about enhancing participation in pharmacovigilance? Br J Clin Pharmacol. 2013;75(4):1109–1117.
   PubMed Web of Science ®Google Scholar
• Härmark L, Lie-Kwie M, Berm L, et al. Patients’ motives for participating in active post-marketing surveillance. Pharmacoepidemiol Drug Saf. 2013;22(1):70–76.
   PubMed Web of Science ®Google Scholar
• Robertson J, Newby DA. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med j Aust. 2013;199(10):684–686.
   PubMed Web of Science ®Google Scholar
• Elkalmi R, Hassali MA, Al-Lela OQ, et al. Adverse drug reactions reporting: knowledge and opinion of general public in Penang, Malaysia. J Pharm Bioallied Sci. 2013;5(3):224–228.
   PubMedGoogle Scholar
• Jha N, Rathore DS, Shankar PR, et al. Pharmacovigilance knowledge among patients at a teaching hospital in Lalitpur District, Nepal. J Clin Diagn Res. 2014;8(3):32–34.
   PubMedGoogle Scholar
• Parrella A, Gold M, Braunack-Mayer A, et al. Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI. Hum Vaccin Immunother. 2014;10(3):747–754.
   PubMed Web of Science ®Google Scholar
• Rolfes L, Wilkes S, van Hunsel F, et al. Important information regarding reporting of adverse drug reactions: a qualitative study. Int J Pharm Pract. 2014;22(3):231–233.
   PubMedGoogle Scholar
• Matos C, van Hunsel F, Joaquim J. Are consumers ready to take part in the pharmacovigilance system?–a Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;71(7):883–890.
   PubMed Web of Science ®Google Scholar
• Sales I, Aljadhey H, Albogami Y, et al. Public awareness and perception toward adverse drug reactions reporting in Riyadh, Saudi Arabia. Saudi Pharm J. 2017;25(6):868–872.
   PubMed Web of Science ®Google Scholar
• Aslani P, Hamrosi K, Tong V, et al. Consumer opinions on adverse events associated with medicines and vaccines. Patient Prefer Adherence. 2018;12:1383–1392.
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez E, Herdeiro MT, Pineiro-Lamas M, et al. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Saf. 2015;38(2):189–196.
   PubMed Web of Science ®Google Scholar
• Terblanche A, Meyer JC, Godman B, et al. Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. Hosp Pract. 2018;46(4):221–228.
   PubMedGoogle Scholar
• Bäckström M, Mjörndal T, Dahlqvist R. Spontaneous reporting of adverse drug reactions by nurses. Pharmacoepidemiol Drug Saf. 2002;11(8):647–650.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Spooner LM. Adverse-drug-reaction reporting by pharmacy students in a teaching hospital. Am J Health Syst Pharm. 2008;65(12):1177–1179.
   PubMed Web of Science ®Google Scholar
• Bisht M, Singh S, Dhasmana DC. Effect of educational intervention on adverse drug reporting by physicians: a cross-sectional study. ISRN Pharmacol. 2014;2014:259476.
   PubMedGoogle Scholar
• Avong YK, Jatau B, Gurumnaan R, et al. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: a prospective cohort study. PLoS One. 2018;13(8):e0200810.
   PubMed Web of Science ®Google Scholar
• Herdeiro MT, Ribeiro-Vaz I, Ferreira M, et al. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf. 2012;35(8):655–665.
   PubMed Web of Science ®Google Scholar
• Gerritsen R, Faddegon H, Dijkers F, et al. Effectiveness of pharmacovigilance training of general practitioners. Drug Saf. 2011;34(9):755–762.
   PubMed Web of Science ®Google Scholar
• Castel JM, Figueras A, Pedrós C, et al. Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Saf. 2003;26(14):1049–1055.
   PubMed Web of Science ®Google Scholar
• Biagi C, Montanaro N, Buccellato E, et al. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013;69(2):237–244.
   PubMed Web of Science ®Google Scholar
• Johansson ML, Hagg S, Wallerstedt SM. Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clin Pharmacol. 2011;11(1):14.
   PubMedGoogle Scholar
• Johansson M-L, Brunlöf G, Edward C, et al. Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. Eur J Clin Pharmacol. 2009;65(5):511–514.
   PubMed Web of Science ®Google Scholar
• Linder JA, Haas JS, Iyer A, et al. Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting. Pharmacoepidemiol Drug Saf. 2010;19(12):1211–1215.
   PubMed Web of Science ®Google Scholar
• Ribeiro-Vaz I, Santos C, da Costa-Pereira A, et al. Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Saf. 2012;35(5):387–394.
   PubMed Web of Science ®Google Scholar
• Abadie D, Chebane L, Bert M, et al. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center. Therapie. 2014;69(5):395–400.
   PubMed Web of Science ®Google Scholar
• Lander AR, Blicher TM, Jimenez-Solem E, et al. Introducing an adverse drug event manager. Eur J Hosp Pharm Sci Pract. 2013;20(2):78–81.
   Google Scholar
• Yen Y-H, Kuo L-N, Hsu M-H, et al. Evaluation of the electronic adverse drug event management system. J Exper Clin Medi. 2010;2(6):287–291.
   Google Scholar
• Ribeiro-Vaz I, Herdeiro MT, Polonia J, et al. Strategies to increase the sensitivity of pharmacovigilance in Portugal. Revista de saude publica. 2011;45(1):129–135.
   PubMed Web of Science ®Google Scholar
• Morales Rios O, Jasso Gutierrez L, Talavera JO, et al. A comprehensive intervention for adverse drug reactions identification and reporting in a pediatric emergency department. Int J Clin Pharm. 2016;38(1):80–87.
   PubMed Web of Science ®Google Scholar
• Chang F, Xi Y, Zhao J, et al. A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. J Eval Clin Pract. 2017;23(6):1316–1321.
   PubMed Web of Science ®Google Scholar
• Fang H, Lin X, Zhang J, et al. Multifaceted interventions for improving spontaneous reporting of adverse drug reactions in a general hospital in China. BMC Pharmacol Toxicol. 2017;18(1):49.
   PubMed Web of Science ®Google Scholar
• Perkerson KA, Quercia RA, Goldman M, et al. Can a multidisciplinary initiative to increase adverse drug reaction reporting work? Conn Med. 2004;68(5):281–284.
   PubMedGoogle Scholar
• Lee S-B, Schepers GP, Goldberg KL. Electronic adverse-drug-reaction-reporting program. Am J Health Syst Pharm. 2004;61(12):1230–1232.
   PubMed Web of Science ®Google Scholar
• Pedrós C, Vallano A, Cereza G, et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Saf. 2009;32(1):77–83.
   PubMed Web of Science ®Google Scholar
• Tabali M, Jeschke E, Bockelbrink A, et al. Educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine. BMC Public Health. 2009;9(1):274.
   PubMedGoogle Scholar
• Clarkson A, Ingleby E, Choonara I, et al. A novel scheme for the reporting of adverse drug reactions. Arch Dis Child. 2001;84(4):337–339.
   PubMed Web of Science ®Google Scholar
• Bracchi RC, Houghton J, Woods FJ, et al. A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme. Br J Clin Pharmacol. 2005;60(2):221–223.
   PubMed Web of Science ®Google Scholar
• Gony M, Badie K, Sommet A, et al. Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrénées region (PharmacoMIP) network 2-year pilot study. Drug Saf. 2010;33(5):409–416.
   PubMed Web of Science ®Google Scholar
• Figueiras A, Herdeiro MT, Polónia J, et al. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Jama. 2006;296(9):1086–1093.
   PubMed Web of Science ®Google Scholar
• Herdeiro MT, Polónia J, Gestal-Otero JJ, et al. Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Saf. 2008;31(4):335–344.
   PubMed Web of Science ®Google Scholar
• Valente SM. Improving professional practice through certification. J Nurses Staff Dev. 2010;26(5):215–219.
   PubMedGoogle Scholar
• Potlog Shchory M, Goldstein LH, Arcavi L, et al. Increasing adverse drug reaction reporting-How can we do better? PLoS One. 2020;15(8):e0235591.
   PubMed Web of Science ®Google Scholar
• Zuccarelli M, Micallef B, Butler D, et al. Improving the data quality of spontaneous ADR reports: a practical example from Malta. Expert Opin Drug Saf. 2022;21(2):253–268.
   PubMed Web of Science ®Google Scholar
• Avillach P, Dufour JC, Diallo G, et al. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. J Am Med Inform Assoc. 2013;20(3):446–452.
   PubMed Web of Science ®Google Scholar
• Trifirò G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176–1184.
   PubMed Web of Science ®Google Scholar
• Arnaud M, Bégaud B, Thiessard F, et al. An automated system combining safety signal detection and prioritization from healthcare databases: a pilot study. Drug Saf. 2018;41(4):377–387.
   PubMed Web of Science ®Google Scholar
• McMaster C, Liew D, Keith C, et al. A machine-learning algorithm to optimise automated adverse drug reaction detection from clinical coding. Drug Saf. 2019;42(6):721–725.
   PubMed Web of Science ®Google Scholar
• Bahk CY, Goshgarian M, Donahue K, et al. Increasing patient engagement in pharmacovigilance through online community outreach and mobile reporting applications: an analysis of adverse event reporting for the essure device in the US. Pharm Med. 2015;29(6):331–340.
   PubMedGoogle Scholar
• Pierce CE, De Vries ST, Bodin-Parssinen S, et al. Recommendations on the use of mobile applications for the collection and communication of pharmaceutical product safety information: lessons from IMI WEB-RADR. Drug Saf. 2019;42(4):477–489.
   PubMed Web of Science ®Google Scholar
• de Vries ST, Wong L, Sutcliffe A, et al. Factors influencing the use of a mobile app for reporting adverse drug reactions and receiving safety information: a qualitative study. Drug Saf. 2017;40(5):443–455.
   PubMed Web of Science ®Google Scholar
• Ghosh R, Lewis D. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media. Expert Opin Drug Saf. 2015;14(12):1845–1853.
   PubMed Web of Science ®Google Scholar
• Michie S, van Stralen M, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42.
   PubMed Web of Science ®Google Scholar
• Radecka A, Loughlin L, Foy M, et al. Enhancing pharmacovigilance capabilities in the EU regulatory network: the SCOPE joint action. Drug Saf. 2018;41(12):1285–1302.
   PubMed Web of Science ®Google Scholar